Effect of cholagogia on the pharmacokinetic profile of a sustained release theophylline formulation

被引:0
|
作者
Fuchs, WS
von Nieciecki, A
Molz, KH
Popescu, G
Weil, A
Barkworth, MF
Gay, S
Laicher, A
Stanislaus, F
机构
[1] Klinge Pharma GMBH, Abt Pharmakokinetik & Biopharm, D-81610 Munchen, Germany
[2] APEX Gesell Angew Pharmakol, Munchen, Germany
来源
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH | 1998年 / 48卷 / 5A期
关键词
antiasthmatics; Bronchoretard (R); CAS; 58-55-9; theophylline; clinical studies; dose dumping; effect of cholagogia;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Bile excretion changes the physiological milieu of the duodenum, possibly resulting in enhanced absorption of a drug due to increased solubilisation. This possible influence of bile salts following stimulation of gallbladder emptying by the release of cholecystokinin on the pharmacokinetics of a sustained release theophylline (CAS 58-55-9) preparation (Bronchoretard(R)) was evaluated in this study. An open, randomised, 3-way crossover study in 12 healthy, non-smoking volunteers was selected to prove or reject this hypothesis. All subjects received 500 mg of the sustained release theophylline formulation under two different cholagogia stimulating test conditions compared with a fasting reference condition. A standard breakfast and i.m. administration of cholecystokinin enabled a reproducible modulation of bile flow: a moderate and extreme contraction of the gallbladder could be induced after a standard breakfast and after i.m. administration of cholecystokinin, respectively. Following a standard breakfast, gallbladder volumes were approximately halved (50.6 %) compared to the baseline volume after 79 min. Injection of 0.3 mu g/kg body weight cholecystokinin resulted in fast and complete gallbladder evacuation (94.6 %) 36 min after the application of this cholagogue stimulus. Gallbladder Volumes remained more or less constant under fasting conditions. This manipulation of bile flow did not influence concentration/time profiles of the sustained release theophylline preparation compared to the fasting condition. Even almost complete evacuation of the gallbladder after administration of cholecystokinin did not modify the concentration/time profile of theophylline in a relevant way. An unintentional rapid release of theophylline could be excluded for this sustained release formulation for all three treatments, as not a single case of dose dumping was observed. Furthermore, in vitro dissolution investigations using synthetic surfactants can predict neither food effects nor bile influence on the in vivo absorption at least for the sustained release formulation tested.
引用
收藏
页码:597 / 604
页数:8
相关论文
共 50 条
  • [1] Effect of gallbladder contraction induced cholagogia on the pharmacokinetic profile of a sustained-release theophylline formulation
    Fuchs, WS
    vonNieciecki, A
    Molz, KH
    Popescu, G
    Weil, A
    Barkworth, MF
    Gay, S
    Laicher, A
    Stanislaus, F
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1996, 46 (12): : 1120 - 1126
  • [2] Pharmacokinetic characteristics of a new liquid sustained release formulation of theophylline -: Microcaps as sachet
    Fuchs, WS
    Weiss, G
    von Nieciecki, A
    Laicher, A
    Gay, S
    Pabst, G
    Müller, R
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 612 - 617
  • [3] Absorption profile and absolute bioavailability of a theophylline sustained release preparation
    Pabst, G
    Weber, W
    Barkworth, MF
    Müller, M
    Rehm, KD
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 574 - 579
  • [4] Pharmacokinetic characteristics of a new liquid sustained-release formulation of theophylline designed for the elderly and children: Microcaps as sachet
    Fuchs, WS
    Weiss, G
    VonNieciecki, A
    Laicher, A
    Gay, S
    Pabst, G
    Muller, M
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1996, 34 (12) : 558 - 563
  • [5] In vivo verification of the in vitro release specification of a sustained release theophylline preparation
    von Nieciecki, A
    Fuchs, WS
    Pabst, G
    Müller, M
    Dilger, C
    Gay, S
    Laicher, A
    Stanislaus, F
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 580 - 583
  • [6] Product quality requirements for sustained release theophylline preparations
    Fuchs, WS
    Hens, C
    von Nieciecki, A
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (5A): : 556 - 561
  • [7] EFFECT OF PRETREATMENT WITH RANITIDINE ON THE PHARMACOKINETICS AND GASTROINTESTINAL TRANSIT OF A SUSTAINED-RELEASE THEOPHYLLINE PREPARATION
    WILSON, CG
    WASHINGTON, N
    GREAVES, JL
    BLACKSHAW, PE
    PERKINS, AC
    BARKWORTH, MF
    REHM, KD
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1991, 41-2 (11): : 1154 - 1159
  • [8] Formulation study and drug release mechanism of a new theophylline sustained-release preparation
    Hayashi, T
    Kanbe, H
    Okada, M
    Suzuki, M
    Ikeda, Y
    Onuki, Y
    Kaneko, T
    Sonobe, T
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 304 (1-2) : 91 - 101
  • [9] Single dose study of the bioequivalence of two sustained-release theophylline formulations
    Contreras, J
    Pérez, N
    González, R
    Ontivero, E
    López, M
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 1998, 48 (03): : 259 - 262
  • [10] PHARMACOKINETIC EVALUATION OF SUSTAINED-RELEASE FORMULATIONS OF THEOPHYLLINE BY ANALOG HYBRID SIMULATION
    MRHAR, A
    RUBESSA, F
    KARBA, R
    MONEGHINI, M
    PRIMOSIC, S
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 62 (01) : 15 - 19